Evidence map›Paper›PMID 41670630›Full record

ArticleEuropean journal of nuclear medicine and molecular imaging2026

Exploring extended [

Matthias Weissinger, Stephan Ursprung, Johann Jacoby, Jonas Vogel, Eduardo Calderón, Brigitte Gückel, Fabian Schmidt, Johannes Schwenck, Helmut Dittmann, Konstantin Nikolaou and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European journal of nuclear medicine and molecular imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Matthias WeissingerNuclear Medicine and Clinical Molecular Imaging, Department of Radiology, University Hospital of Tuebingen, Otfried-Mueller-Strasse 14, 72076, Tuebingen, Germany.
Stephan UrsprungDiagnostic and Interventional Radiology, University Department of Radiology, University Hospital of Tuebingen, Hoppe-Seyler-Str. 3, 72076, Tuebingen, Germany.
Johann JacobyInstitute for Clinical Epidemiology and Applied Biometry, University Hospital Tuebingen, Silcherstr. 5, 72076, Tuebingen, Germany.
Jonas VogelNuclear Medicine and Clinical Molecular Imaging, Department of Radiology, University Hospital of Tuebingen, Otfried-Mueller-Strasse 14, 72076, Tuebingen, Germany.
Eduardo CalderónNuclear Medicine and Clinical Molecular Imaging, Department of Radiology, University Hospital of Tuebingen, Otfried-Mueller-Strasse 14, 72076, Tuebingen, Germany.
Brigitte GückelNuclear Medicine and Clinical Molecular Imaging, Department of Radiology, University Hospital of Tuebingen, Otfried-Mueller-Strasse 14, 72076, Tuebingen, Germany.
Fabian SchmidtNuclear Medicine and Clinical Molecular Imaging, Department of Radiology, University Hospital of Tuebingen, Otfried-Mueller-Strasse 14, 72076, Tuebingen, Germany.
Johannes SchwenckNuclear Medicine and Clinical Molecular Imaging, Department of Radiology, University Hospital of Tuebingen, Otfried-Mueller-Strasse 14, 72076, Tuebingen, Germany.
Helmut DittmannNuclear Medicine and Clinical Molecular Imaging, Department of Radiology, University Hospital of Tuebingen, Otfried-Mueller-Strasse 14, 72076, Tuebingen, Germany.
Konstantin NikolaouDiagnostic and Interventional Radiology, University Department of Radiology, University Hospital of Tuebingen, Hoppe-Seyler-Str. 3, 72076, Tuebingen, Germany.
Christian la FougèreNuclear Medicine and Clinical Molecular Imaging, Department of Radiology, University Hospital of Tuebingen, Otfried-Mueller-Strasse 14, 72076, Tuebingen, Germany.
Christian Philipp ReinertNuclear Medicine and Clinical Molecular Imaging, Department of Radiology, University Hospital of Tuebingen, Otfried-Mueller-Strasse 14, 72076, Tuebingen, Germany. christian.reinert@med.uni-tuebingen.de.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThis prospective trial investigated extended [

methodsFifteen consecutive, treatment- naïve lymphoma patients (4 Hodgkin, 11 non-Hodgkin) underwent routine whole-body [

resultsImage quality remained diagnostic in all datasets. Median Tumour-to-Background Ratio (TBR) increased significantly from 4.1 (1 h p.i.) to 12.5 (3 h p.i.) and 23.9 (6 h p.i.), p < 0.001. High-grade lymphoma exhibited an almost linear SUV rise, whereas low-grade entities followed a parabolic course, peaking at 3 h p.i. Benign lymph nodes demonstrated constant uptake (1 h: 0.9 ± 0.3, 3 h: 0.8 ± 0.5, 6 h: 0.8 ± 0.4). RIs showed a significant increase in [

conclusionThe LAFOV scanner enables high-quality [

trial registrationDRKS00027307. Registered 26 November 2021.

Indexed as

Fluorodeoxyglucose F18LymphomaPositron Emission Tomography Computed TomographyAgedFemaleHumansKineticsMaleMiddle AgedRadiopharmaceuticalsTime FactorsFluorodeoxyglucose F18Radiopharmaceuticals[18F]FDG efflux[18F]FDG kineticDelayed LAFOV PETGlucose-6-phosphatase-β activity, [18F]FDG trappingMulti Time-Point kineticUltra-late PET

Identifiers

PMID41670630
PMCPMC13197291

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.